![](/images/graphics-bg.png)
Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients
المؤلفون المشاركون
Rudiger, Alain
Arrigo, Mattia
Salzberg, Sacha P.
Bettex, Dominique
Breitenstein, Alexander
المصدر
Critical Care Research and Practice
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-05-12
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objectives.
This study investigates the suitability, safety, and efficacy of vernakalant in critically ill patients with new onset atrial fibrillation (AF) after cardiac surgery.
Methods.
Patients were screened for inclusion and exclusion criteria according to the manufacturers’ recommendations.
Included patients were treated with 3 mg/kg of vernakalant over 10 min and, if unsuccessful, a second dose of 2 mg/kg.
Blood pressure was measured continuously for 2 hours after treatment.
Results.
Of the 191 patients screened, 159 (83%) were excluded, most importantly due to hemodynamic instability (59%).
Vernakalant was administered to 32 (17% of the screened) patients.
Within 6 hours, 17 (53%) patients converted to sinus rhythm.
Blood pressure did not decrease significantly 10, 30, 60, and 120 minutes after the vernakalant infusion.
However, 11 patients (34%) experienced a transient decrease in mean arterial blood pressure <60 mmHg.
Other adverse events included nausea (n=1) and bradycardia (n=2).
Conclusions.
Applying the strict inclusion and exclusion criteria provided by the manufacturer, only a minority of postoperative ICU patients with new onset AF qualified for vernakalant.
Half of the treated patients converted to sinus rhythm.
The drug was well tolerated, but close heart rate and blood pressure monitoring remains recommended.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Rudiger, Alain& Breitenstein, Alexander& Arrigo, Mattia& Salzberg, Sacha P.& Bettex, Dominique. 2014. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-501209
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Rudiger, Alain…[et al.]. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-501209
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Rudiger, Alain& Breitenstein, Alexander& Arrigo, Mattia& Salzberg, Sacha P.& Bettex, Dominique. Suitability, Efficacy, and Safety of Vernakalant for New Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-501209
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-501209
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)